Men With Hemoglobin Increase in Participants Who Had Anemia at Baseline
anemia
REGRESSION, CARDIOVASCULAR DISEASE, ANEMIA
Frequencies and relative risks of hemoglobin increase of more than 1.0 g/dL above baseline in the TRT group relative to the placebo group and the associated 95% CIs at each visit in men who had anemia at baseline are shown by treatment group and time point. The risk ratio of hemoglobin increase of more than 1.0 g/dL in the TRT vs placebo group was estimated by a repeated measures log-binomial regression with fixed effects for treatment, visit, treatment-visit interaction, preexisting cardiovascular disease, and a random per-subject repeated measures effect using an unstructured covariance matrix. The omnibus test Among participants with anemia at baseline, hemoglobin levels increased significantly more in the TRT than placebo group at 6 months (between-group least square mean difference, 0.37 g/dL; 95% CI, 0.21 to 0.53 g/dL), 12 months (0.33 g/dL; 95% CI, 0.13 to 0.53 g/dL), 24 months (0.25 g/dL; 95% CI, −0.02 to 0.53 g/dL), 36 months (0.35 g/dL; 95% CI, 0.04 to 0.67 g/dL), and 48 months (−0.05 g/dL; 95% CI, −0.49 to 0.39 g/dL) (omnibus 